Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › olaparib

olaparib

4 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of olaparib

44 trials tracked of olaparib: 14 in phase 3 or 4 and 11 with published results. The most-cited published study has 3199 citations.

44Trials tracked
14Phase 3 & 4
0Recruiting
11With published results
Phase distribution
Phase 4 2 Phase 3 12 Phase 2 23 Phase 1 6 Other / NA 1
  1. Phase 3 Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations. Completed · 3,199 cited
  2. Phase 3 Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments Completed · 295 cited
  3. Phase 3 Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer. Completed · 291 cited
  4. Phase 3 Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy Completed · 222 cited
  5. Phase 3 Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010) Completed · 131 cited
  6. Phase 3 Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study) Completed · 91 cited
Show 38 more trials
  1. Phase 3 Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer Patients Completed · 56 cited
  2. Phase 3 To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients. Completed · 33 cited
  3. Phase 3 Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/LYNK-003) Completed · 13 cited
  4. Phase 3 Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006) Completed · 6 cited
  5. Phase 3 A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008) Completed · 4 cited
  6. Phase 4 To Assess the Efficacy and Safety of Olaparib Maintenance Monotherapy in the Treatment of Ovarian Cancer Completed
  7. Phase 4 Prospective Multicentre Phase-IV Clinical Trial of Olaparib in Indian Patients With Ovarian and Metastatic Breast Cancer Completed
  8. Phase 3 Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036) Completed
  9. Phase 2 Efficacy Study of Olaparib With Paclitaxel Versus Paclitaxel in Gastric Cancer Patients Completed
  10. Phase 2 Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer. Completed
  11. Phase 2 Pembrolizumab in Combination With Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancer Completed
  12. Phase 2 Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation Completed
  13. Phase 2 Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) Completed
  14. Phase 2 Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status Completed
  15. Phase 2 Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations Completed
  16. Phase 2 Study of Pembrolizumab and Olaparib in Bile Duct Cancer Completed
  17. Phase 2 A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site Completed
  18. Phase 2 Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery Completed
  19. Phase 2 Olaparib in People With Malignant Mesothelioma Completed
  20. Phase 2 Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) Status Completed
  21. Phase 2 Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma Completed
  22. Phase 2 Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancer Completed
  23. Phase 2 Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer Completed
  24. Phase 2 Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats Completed
  25. Phase 2 Olaparib in Adults With Recurrent/Metastatic Ewing's Sarcoma Completed
  26. Phase 2 Analysis of Olaparib Response in Patients With BRCA1 and/or 2 Promoter Methylation Diagnosed of Advanced Breast Cancer Completed
  27. Phase 2 Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009) Completed
  28. Phase 2 Olaparib in Treating Patients With Stage IV Pancreatic Cancer Completed
  29. Phase 2 Study With Gefitinib in Combination With Olaparib (AZD2281) Versus Gefitinib Alone Completed
  30. Phase 2 Study to Assess The Efficacy and Safety of a PARP Inhibitor For The Treatment of BRCA-positive Advanced Breast Cancer Completed
  31. Phase 2 Best Approach in Recurrent-Ovarian-Cancer-with Cediranib-Olaparib Completed
  32. Phase 1 The Pharmacokinetics and Safety of Olaparib Alone and With Paclitaxel in Chinese Patients With Advanced Solid Tumour. Completed
  33. Phase 1 Investigate the Safety and Tolerability of Olaparib Tablet in Japanese Patients With Advanced Solid Malignancies Completed
  34. Phase 1 A Study of Olaparib With Concomitant Radiotherapy in Locally Advanced/Unresectable Soft-tissue Sarcoma Completed
  35. Phase 1 Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer Completed
  36. Phase 1 To Assess Safety and Effect of Olaparib on the Pharmacokinetics of Anastrozole, Letrozole & Tamoxifen, and Their Effect on Olaparib, in Patients With Advanced Solid Cancer Completed
  37. Phase 1 Study of Olaparib With Radiation Therapy and Cetuximab in Advanced Head and Neck Cancer With Heavy Smoking History Completed
  38. N/A Preoperative Olaparib Endometrial Carcinoma Study (POLEN) Completed

Showing the 44 most-cited and recently-updated of 44 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Case report of YL205 antibody-drug conjugate in platinum-resistant ovarian carcinoma
Infectious Disease Sys. Review
Case report of YL205 antibody-drug conjugate in platinum-resistant ovarian carcinoma First patient achieves complete response with new ovarian cancer drug YL205
This is a single-patient case report of a 40-year-old woman with platinum-resistant, BRCA-wildtype high-grade serous ovarian carcinoma treat…
A single patient with advanced ovarian cancer achieved a complete response after 24 weeks of treatment with YL205, a new antibody-drug conju…
Frontiers May 22, 2026
Review of ovarian cancer treatments including olaparib, bevacizumab, and durvalumab discusses limitations and biomarkers
Allergy & Immunology Sys. Review
Review of ovarian cancer treatments including olaparib, bevacizumab, and durvalumab discusses limitations and biomarkers New drug combos target hidden cancer switches to stop resistance
This narrative review examines ovarian cancer management involving olaparib, bevacizumab, and durvalumab.
Hidden chemical changes in ovarian cancer cells help them hide from drugs, but new combinations might finally stop them from adapting and gr…
Frontiers May 1, 2026
Olaparib plus durvalumab showed activity in mCRPC patients previously treated with abiraterone or enzalutamide
Oncology Phase II
Olaparib plus durvalumab showed activity in mCRPC patients previously treated with abiraterone or enzalutamide Two Cancer Drugs Teamed Up — Who Actually Benefits Most?
This single-arm, open-label phase 2 trial evaluated olaparib plus durvalumab in 60 men with metastatic castration-resistant prostate cancer …
A new prostate cancer drug combo helped men with specific DNA repair gene variants live more than twice as long without their cancer progres…
Apr 10, 2026
RAD51-foci Score Predicts Olaparib Efficacy in Advanced HER2-negative Breast Cancer
OB/GYN & Women's Health Phase II
RAD51-foci Score Predicts Olaparib Efficacy in Advanced HER2-negative Breast Cancer Could a Simple Test Help Tailor Breast Cancer Treatment?
Phase II study shows RAD51-foci score predicts olaparib response in BRCA1/2, PALB2, RAD51C/D mutated breast cancer. Study enrolled 65 patien…
A new test may help doctors choose the right drug sooner for women with advanced breast cancer who have specific genetic mutations.
CT.gov Mar 27, 2026